Biogen Idec's Tysabri May Return To Market In 2006 - Forbes.com

"While PML [progressive multifocal leukoencephalopathy] concerns are legitimate, we believe many neurologists will accept the risk/benefit tradeoff and adoption rates could exceed expectations." MORE - Forbes.com